Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma.
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial / Ascierto, Paolo A; Mandalà, Mario; Ferrucci, Pier Francesso; Guidoboni, Massimo; Rutkowski, Piotr; Ferraresi, Virginia; Arance, Ana; Guida, Michele; Maiello, Evaristo; Gogas, Helen; Richtig, Erika; Fierro, Maria Teresa; Lebbè, Celeste; Helgadottir, Hildur; Queirolo, Paola; Spagnolo, Francesco; Tucci, Marco; Del Vecchio, Michele; Gonzales Cao, Maria; Minisini, Alessandro Marco; De Placido, Sabino; Sanmamed, Miguel F; Mallardo, Domenico; Curvietto, Marcello; Melero, Ignacio; Palmieri, Giuseppe; Grimaldi, Antonio M; Giannarelli, Diana; Dummer, Reinhard; Chiarion Sileni, Vanna. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - (2023), pp. 2961-2969. [10.1200/JCO.21.02961]
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Palmieri, GiuseppeInvestigation
;
2023-01-01
Abstract
Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
